FDA: untapped source of unpublished trials

[1]  Gerd Antes,et al.  Under-reporting of clinical trials is unethical , 2003, The Lancet.

[2]  J. Rodés,et al.  Role of a research ethics committee in follow-up and publication of results , 2003, The Lancet.

[3]  P. Shekelle,et al.  How useful are unpublished data from the Food and Drug Administration in meta-analysis? , 2003, Journal of clinical epidemiology.

[4]  Douglas G. Altman,et al.  Systematic Reviews in Health Care: Meta-Analysis in Context: Second Edition , 2008 .

[5]  Jonathan A C Sterne,et al.  Systematic reviews in health care: Investigating and dealing with publication and other biases in meta-analysis. , 2001, BMJ.

[6]  D. Moher,et al.  The Revised CONSORT Statement for Reporting Randomized Trials: Explanation and Elaboration , 2001, Annals of Internal Medicine.

[7]  Alex J. Sutton,et al.  Modelling publication bias in meta-analysis: a review , 2000 .

[8]  J. Ioannidis.  Effect of the statistical significance of results on the time to completion and publication of randomized efficacy trials. , 1998, JAMA.

[9]  R. Simes,et al.  Publication bias: evidence of delayed publication in a cohort study of clinical research projects , 1997, BMJ.

[10]  Cindy Farquhar,et al.  3 The Cochrane Library , 1996 .

[11]  A R Jadad,et al.  Assessing the quality of reports of randomized clinical trials: is blinding necessary? , 1996, Controlled clinical trials.

[12]  I Chalmers,et al.  Underreporting research is scientific misconduct. , 1990, JAMA.

[13]  C. Begg,et al.  Publication bias : a problem in interpreting medical data , 1988 .